Lea Hachigian, ImmuneID
Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup
Lea Hachigian, a principal at the Longwood Fund, recalls working with Harvard professor Stephen Elledge three years ago on the launch of TCR-focused TScan Therapeutics. Elledge initially set out to screen antigen-TCR matches in a faster, more systematic way and spent seven years putting together the tech for a platform that could run multiple T cell receptors against antigen epitopes and pinpoint the exact pairs that appear to interact.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters